Innovations in Bladder Cancer Treatment

This chapter explores the Sunrise 4 trial, which evaluates the combination of TAR-200 and citalumab for muscle invasive bladder cancer patients. It discusses the promising results, treatment adverse events, and highlights the latest advancements in clinical research impacting bladder cancer therapies.